In modern medicine, diabetes remains a global healthcare priority. As a complex metabolic disorder, it not only impairs patients’ quality of life but also triggers a series of severe complications.
Although conventional interventions alleviate symptoms to a certain extent, they fail to fundamentally resolve the underlying disease. However, with the rapid advancement of regenerative medicine, mesenchymal stem cells (MSCs) and their derived exosomes have brought new hope for diabetes management.
We once regarded stem cells as a panacea, until research revealed that fewer than 5% of transplanted stem cells survive long-term in diabetic patients.
Therefore, scientists began exploring novel alternatives to intact MSC transplantation, and MSC-derived exosomes have gradually emerged as a promising candidate. A high-quality review titled Mesenchymal Stem Cell-Derived Exosomes: A Highly Promising Strategy for Diabetes Remission was published in Biomimetics in 2025.
In Type 1 Diabetes Mellitus (T1DM), pancreatic β-cells are destroyed by autoimmune responses, leading to absolute insulin deficiency. MSC-derived exosomes ameliorate T1DM symptoms by regulating immune reactions and promoting β-cell regeneration.
In Type 2 Diabetes Mellitus (T2DM), insulin resistance and pancreatic β-cell dysfunction are the core pathological features. MSC-derived exosomes improve T2DM manifestations by enhancing insulin sensitivity and mitigating chronic inflammation.
Given the remarkable potential of MSC-derived exosomes in relieving diabetic symptoms, I firmly believe they possess broad prospects for future clinical application.
Compared with traditional therapeutic strategies, MSC-derived exosomes exhibit multiple advantages, including low immunogenicity, high biological stability, and convenience for storage and transportation.
Furthermore, surface modification enables targeted delivery of MSC-derived exosomes to lesion sites, thereby enhancing therapeutic efficacy. These properties make MSC-derived exosomes an ideal cell-free therapeutic modality.
In future comprehensive diabetes management regimens, MSC-derived exosomes are expected to bring new hope to diabetic patients by modulating immune homeostasis, protecting functional β-cells, and reversing insulin resistance.